63 research outputs found
HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer
Type II endometrial cancers (uterine serous papillary and clear cell histologies) represent rare but highly aggressive variants of endometrial cancer (EC). HER2 and EGFR may be differentially expressed in type II EC. Here, we evaluate the clinical role of HER2 and EGFR in a large cohort of surgically staged patients with type II (nonendometrioid) EC and compare the findings with those seen in a representative cohort of type I (endometrioid) EC. In this study HER2 gene amplification was studied by fluorescence in situ hybridisation (FISH) and EGFR expression by immunohistochemistry. Tissue microarrays were constructed from 279 patients with EC (145 patients with type I and 134 patients with type II EC). All patients were completely surgically staged and long-term clinical follow up was available for 258 patients. The rate of HER2 gene amplification was significantly higher in type II EC compared with type I EC (17 vs 1%, P<0.001). HER2 gene amplification was detected in 17 and 16% of the cases with uterine serous papillary and clear cell type histology, respectively. In contrast, EGFR expression was significantly lower in type II compared with type I EC (34 vs 46%, P=0.041). EGFR expression but not HER2 gene amplification was significantly associated with poor overall survival in patients with type II EC, (EGFR, median survival 20 vs 33 months, P=0.028; HER2, median survival 18 vs 29 months, P=0.113) and EGFR expression retained prognostic independence when adjusting for histology, stage, grade, and age (EGFR, P=0.0197; HER2, P=0.7855). We conclude that assessment of HER2 gene amplification and/or EGFR expression may help to select type II EC patients who could benefit from therapeutic strategies targeting both HER2 and EGFR
3D extracellular matrix microenvironment in bioengineered tissue models of primary pediatric and adult brain tumors.
Dynamic alterations in the unique brain extracellular matrix (ECM) are involved in malignant brain tumors. Yet studies of brain ECM roles in tumor cell behavior have been difficult due to lack of access to the human brain. We present a tunable 3D bioengineered brain tissue platform by integrating microenvironmental cues of native brain-derived ECMs and live imaging to systematically evaluate patient-derived brain tumor responses. Using pediatric ependymoma and adult glioblastoma as examples, the 3D brain ECM-containing microenvironment with a balance of cell-cell and cell-matrix interactions supports distinctive phenotypes associated with tumor type-specific and ECM-dependent patterns in the tumor cells\u27 transcriptomic and release profiles. Label-free metabolic imaging of the composite model structure identifies metabolically distinct sub-populations within a tumor type and captures extracellular lipid-containing droplets with potential implications in drug response. The versatile bioengineered 3D tumor tissue system sets the stage for mechanistic studies deciphering microenvironmental role in brain tumor progression
Ovarian cancer immunotherapy: opportunities, progresses and challenges
Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer
S-D logic-informed customer engagement: Integrative framework, revised fundamental propositions, and application to CRM
Advance online in 2016</p
Dissociations in the effects of beta2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: Support for the concept of functional selectivity
In neutrophils, activation of the beta2-adrenergic receptor (beta2AR), a Gs-coupled receptor,
inhibits inflammatory responses, which could be therapeutically exploited. The aim of this study was to
evaluate the effects of various beta2AR ligands on adenosine-3',5'-cyclic monophosphate (cAMP)
accumulation and N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)-induced superoxide anion
(O2*-) production in human neutrophils and to probe the concept of ligand-specific receptor
conformations (also referred to as functional selectivity or biased signaling) in a native cell system.
cAMP concentration was determined by HPLC/tandem mass spectrometry, and O2*- formation was
assessed by superoxide dismutase-inhibitable reduction of ferricytochrome c. beta2AR agonists were
generally more potent in inhibiting fMLP-induced O2*- production than in stimulating cAMP
accumulation. (-)-Ephedrine and dichloroisoproterenol were devoid of any agonistic activity in the
cAMP assay, but partially inhibited fMLP-induced O2*- production. Moreover, (-)-adrenaline was equiefficacious
in both assays whereas the efficacy of salbutamol was more than two-fold higher in the O2*-
assay. In contrast to the agonists, the effects of beta2AR antagonists were comparable between the two
parameters on neutrophils. Differences between the data from neutrophils and recombinant test
systems were observed for the beta2AR agonists as well as for the beta2AR antagonists. Lastly, we
obtained no evidence for an involvement of protein kinase A in the inhibition of fMLP-induced O2*-
production after beta2AR-stimulation, although, in principle, cAMP-increasing substances can inhibit
O2*- production. Taken together, our data corroborate the concept of ligand-specific receptor
conformations with unique signaling capabilities and suggest that the beta2AR inhibits O2*-
production in a cAMP-independent manner
Ventilation/perfusion SPECT for the diagnosis of pulmonary embolism: A systematic review
Why Generalized Structured Component Analysis Is Not Universally Preferable to Structural Equation Modeling
Contains fulltext :
111959.pdf (publisher's version ) (Open Access)27 maart 201212 p
- …